Health Matters

Tag: Weight Loss Market

  • Compounded GLP-1 Injections Spark Regulatory Battle

    South African pharmaceutical firm iDexis is fighting back against local healthcare regulators over its Compounded GLP-1 Weight-Loss Injections. The company strongly defends its product safety amid serious compliance allegations. The dispute follows a joint statement by the South African Health Products Regulatory Authority (SAHPRA) and the South African Pharmacy Council (SAPC). The regulators ordered an immediate recall of the company’s…

    Continue reading with a Health Matters subscription

    Subscribers read every article in full, receive the daily briefing and have access to the complete archive.

    SubscribeLog in

  • Roche CT-388 Obesity Drug Posts 22.5% Weight Loss

    Roche has reported mid-stage results that put its lead obesity candidate closer to the front of a fast-moving race dominated by Eli Lilly and Novo Nordisk. The Swiss group said its once-weekly injectable Roche CT-388 obesity drug achieved up to 22.5% placebo-adjusted weight loss at 48 weeks in a phase 2 trial among participants who adhered to the treatment regimen.…

    Continue reading with a Health Matters subscription

    Subscribers read every article in full, receive the daily briefing and have access to the complete archive.

    SubscribeLog in